213316-49-5

Basic information

• Product Name: (1R,2S)-1-BOC-AMINO-2-VINYLCYCLOPROPANECARBOXYLIC ACID ETHYL ESTER
• Synonyms: (1R,2S)-1-BOC-AMINO-2-VINYLCYCLOPROPANECARBOXYLIC ACID ETHYL ESTER;N-BOC-(1R,2S)-1-AMINO-2-VINYLCYCLOPROPANE CARBOXYLIC ACID ETHYL ESTER;Cyclopropanecarboxylic acid, 1-[[(1,1-dimethylethoxy)carbonyl]amino]-2-ethenyl-, ethyl ester, (1R,2S)-rel-;N-BOC-(1R,2S)-1-AMINO-2-VINYLCYCLOPROPANE CARBOXYL;(1R,2S)-1-[[(tert-Butoxy)carbonyl]amino]-2-ethenyl-cyclopropanecarboxylic acid ethyl ester;(1R,2S)-rel-1-[[(1,1-diMethylethoxy)carbonyl]aMino]-2-ethenyl-Cyclopropanecarboxylic acid ethyl ester;(1R,2S)-1-boc aMino-2-ethenyl cyclopropane forMaic acid;N-BOC-(1R,2S)-1-AMINO-2-VIYCYCLOPROPANE CARBOXYL
• CAS NO: 213316-49-5
• Molecular Formula: C13H21NO4
• Molecular Weight: 255.31
• EINECS: 1533716-785-6
• Product Categories: Amino Acid Derivatives
• Mol File: 213316-49-5.mol
• Article Data: 29

Chemical Properties

• Boiling Point: 328.42 °C at 760 mmHg
• Flash Point: 152.423 °C
• Appearance: /
• Density: 1.08
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (1R,2S)-1-BOC-AMINO-2-VINYLCYCLOPROPANECARBOXYLIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (1R,2S)-1-BOC-AMINO-2-VINYLCYCLOPROPANECARBOXYLIC ACID ETHYL ESTER(213316-49-5)
• EPA Substance Registry System: (1R,2S)-1-BOC-AMINO-2-VINYLCYCLOPROPANECARBOXYLIC ACID ETHYL ESTER(213316-49-5)

Safety Data

• Hazardous Substances Data: 213316-49-5(Hazardous Substances Data)

Usage

Chemical Properties

White powder

InChI:O=C(OCC)[C@]1(NC(=O)OC(C)(C)C)[C@H](\C=C)C1

Upstream product

• 259214-54-5 (trans)-ethyl 1-amino-2-vinylcyclopropanecarboxylate hydrochloride 
• 34619-03-9 tert-butyldicarbonate 
• 259217-95-3 N-Boc-(1R,2S)-1-amino-2-vinylcyclopropane carboxylic acid ethyl ester 
• 75-65-0 tert-butyl alcohol 
• 787548-29-2 (1R,2S)/(1S,2R) 1-amino-2-vinylcyclopropane carboxylic acid ethyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 681807-60-3 (1R,2S)-ethyl 1-amino-2-vinylcyclopropanecarboxylate hydrochloride 
• 213316-32-6 rac-(1R,2S)-1-amino-2-vinylcyclopropanecarboxylic acid ethyl ester 
• 681807-59-0 (1R,2S)-ethyl 1-(tert-butoxycarbonylamino)-2-vinylcyclopropanecarboxylate 
• 1393095-18-5 (E)-ethyl 1-(benzylideneamino)-2-vinylcyclopropanecarboxylate 
• 1023795-84-7 C₂₁H₂₁NO₂ 
• 821-06-7 (E)-1,4-dibromobutene 
• 40682-54-0 ethyl N-benzylideneglycinate 
• 141-78-6 ethyl acetate 

Downstream Products

• 259214-55-6 (1S,2R)-1-tert-butoxycarbonylamino-2-vinylcyclopropanecarboxylic acid 
• 259217-95-3 N-Boc-(1R,2S)-1-amino-2-vinylcyclopropane carboxylic acid ethyl ester 
• 1201943-62-5 (1S,2R)-1-tert-butoxycarbonylamino-2-vinylcyclopropanecarboxylic acid methyl ester 
• 159622-09-0 (1R,2S)-1-tert-butoxycarbonylamino-2-vinyl-cyclopropanecarboxylic acid methyl ester 
• 259214-54-5 (trans)-ethyl 1-amino-2-vinylcyclopropanecarboxylate hydrochloride 
• 259214-54-5 ethyl (1R,2S)-1-amino-2-vinylcyclopropanecarboxylate hydrochloride 
• 259214-54-5 ethyl (1S,2R)-1-amino-2-vinylcyclopropanecarboxylate hydrochloride 
• 630421-48-6 tert-butyl ((1R,2S)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)carbamate 
• 924307-75-5 (1S,2R)-ethyl 2-vinyl-1-(tert-butoxycarbonylamino)cyclopropanecarboxylate 
• 213316-32-6 rac-(1R,2S)-1-amino-2-vinylcyclopropanecarboxylic acid ethyl ester 
• 923591-34-8 tert-butyl ((1R,2R)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-ethylcyclopropyl)carbamate 
• 1152134-45-6 (1R,2R)-1-(tert-butoxycarbonylamino)-2-(difluoromethyl)cyclopropanecarboxylic acid 
• 772337-53-8 (1R,2S)-1-amino-N-(cyclopropylsulfonyl)-2-vinylcyclopropane-1-carboxamide 
• 790305-05-4 tert-butyl (2R,6S,13aS,14aR,16aS,Z)-14a-(cyclopropylsulfonylcarbamoyl)-2-hydroxy-5,16-dioxo-1,2,3,5,6,7,8, 9,10,11,13a,14,14a,15,16,16a-hexadecahydronaphthylcyclopropanoyl[e]pyrrolo[1,2-a][1,4]diazacyclopenta decyne-6-yl-carbamate 

Relevant articles and documents

CALPAIN MODULATORS AND METHODS OF PRODUCTION AND USE THEREOF

The present technology relates to compounds, kits, compositions, and methods useful for the treatment of fibrotic disease. In some aspects, the present technology provides for treatment of various diseases or disorders associated or mediated, at least in part, by calpains, such as CAPN1, CAPN2, and/or CAPN9. The present technology is generally applicable to compounds which inhibit myofibroblast differentiation.

Macrocyclic compounds for suppressing replication of hepatitis C virus

A compound as represented by Formula (I) is provided, wherein groups are defined in the description. The compound is used as HCV protease inhibitor for treating HCV infection.

MACROCYCLIC COMPOUNDS FOR SUPPRESSING REPLICATION OF HEPATITIS C VIRUS

A compound as represented by Formula (I) is provided, wherein groups are defined in the description. The compound is used as HCV protease inhibitor for treating HCV infection.